In April, 2024, Immunorock Co., Ltd. closed the transaction. The company received ¥45.5 million in its second and final tranche from new investor, OUVC Fund 2 Limited Partnership, a fund managed by Osaka University Venture Capital Co., Ltd., an investment arm. The company raised ¥149.5 million in the transaction.